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Abstract
Acne causes profound negative psychological and social effects on the quality of life (QoL) of patients. The European
Dermatology Forum S3-Guideline for the Treatment of Acne recommended adopting a QoL measure as an integral part
of acne management. Because of constantly growing interest in health-related QoL assessment in acne and because of
the high impact of acne on patients’ lives, the European Academy of Dermatology and Venereology Task Force on QoL
and Patient Oriented Outcomes and the Task Force on Acne, Rosacea and Hidradenitis Suppurativa have documented
the QoL instruments that have been used in acne patients, with information on validation, purposes of their usage,
description of common limitations and mistakes in their usage and overall recommendations.
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Acne is a common dermatological diagnosis accounting for 22–
32% of dermatology patients and is one of the most common
reasons for visiting a physician (1.1%)1 with an estimated preva-
lence of 650 million people affected.2 A systematic analysis for
the Global Burden of Disease study indicated that acne was the
8th most prevalent disease globally in 2010.3 Acne is considered
a chronic disease owing to its prolonged course, pattern of
recurrence and relapse, and manifestations such as acute out-
breaks or slow onset. Moreover, the disease causes profound
negative psychological and social effects on the quality of life
(QoL) of patients.4 Most people experience acne during adoles-
cence, with >95% of teenage boys and 85% of teenage girls
affected.5 Of these young people, 20–40% have moderate-to-
severe acne and as many as 50% continue to suffer from acne in
adulthood. Familial predisposition and especially maternal acne
are significantly associated with a more severe course.5 Acne
patients are managed primarily by dermatologists (93%) but also
by general practitioners (6.3%) and paediatricians (0.6%).6 In
2004, the direct annual costs of acne treatment in the USA had
climbed to over 2.2 billion US dollars.7
Patients with clinical acne require medical therapy, either
because of the severity or duration of their disease. Recent scien-
tific advances have contributed to a better understanding of the
pathogenesis of acne and to optimizing the therapeutic
approach.8–12 Health-related QoL (HRQoL) assessment in
patients with acne is recommended by several national guide-
lines.13 The European Dermatology Forum S3-Guideline for the
Treatment of Acne recommended adopting a QoL measure as an
integral part of acne management.14
HRQoL assessment in acne patients is often used in clinical
trials as an outcome measure, but there are also many reasons to
measure HRQoL in clinical practice.15 To facilitate the integra-
tion of thinking about QoL into routine clinical practice, the
new word ‘QUIMP’, meaning quality of life impairment, was
recently proposed.16
Because of growing interest in the assessment of HRQoL in
acne and the major impact of acne on patients’ lives, the Euro-
pean Academy of Dermatology and Venereology (EADV) Task
Forces (TFs) on QoL and Patient Oriented Outcomes (PO) and
Acne, Rosacea and Hidradenitis Suppurativa (ARHS) have doc-
umented the QoL instruments that have been used in acne
patients, with information on validation, purposes of their
usage, description of common limitations and mistakes in their
usage and overall recommendations of the TFs.
This information should assist dermatologists and researchers
in choosing appropriate QoL instruments, avoid common mis-
takes and facilitate the use of validated QoL instruments in their
research and clinical work.
Methods
Members of the EADV TFs on QoL/PO and ARHS were invited
to participate. A literature search was performed using the
PubMed database, which was searched from 1980 to November
2016 using the key words combination: ‘acne’ and ‘quality of
life’. All publications written in English or those having English
abstracts were considered. All those who volunteered were allo-
cated a section of the identified articles to review.
Exclusion criteria:
Review articles, guidelines, protocols;
Studies without HRQoL assessment;
Measurement of HRQoL in conditions other than acne;
Studies where HRQoL was measured in patients with conditions
other than acne but some of whom may also have acne;
Studies where HRQoL was studied in acne and other diseases but
results on acne were not presented and/or discussed separately;
Studies on postacne scars and postacne hyperpigmentation.
All publications were independently assessed by two co-
authors. The assessments were compared and discrepancies dis-
cussed and resolved. The remaining publications were analysed
in detail, and the QoL instruments used in acne were listed.
Additional PubMed searches were carried out for ‘acne’ and the
name of each of the measures from this list.
Results
Thirteen members of the EADV TFs took part in the literature
review. Figure 1 shows the literature search procedure. Validated
HRQoL instruments that were used in acne studies are described
in Table 1. Figure 2 shows how frequently these instruments
were used.
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P€arna et al.17 used the RAND-36 instrument: this has identi-
cal content to the SF-36 but has a slightly different scoring sys-
tem. Acne patients were included in the creation and initial
validation of the 11-item Turkish quality of life (TQL) instru-
ment.18 The Children’s Life Quality Index (CLQI), a 12-item
generic proxy instrument has been used to compare children
with skin disease with children with other chronic diseases.19
Two German instruments were also used to assess HRQoL in
acne patients.20,21
Truchuelo et al.22 reported the use of the 9-item Social Qual-
ity-of-Life (SOQOL) scale, citing Krejci-Manwaring et al.23
However, Krejci-Manwaring et al.23 do not give information on
the 9-item instrument. Nair and Nair appear to have combined
the DLQI and CADI under the title Total Acne Quality of Life
(TAQOL).24 Five ‘study-specific’ untitled questionnaires with
QoL elements were also used in acne patients.25–29
There are several reports of acne studies in which QoL instru-
ments were used outside their validated age limits. For example,
Skindex-29, an instrument for adults, was used in children from
12 years old,30 and the DLQI, designed for use in those over
16 years old, was used in children aged 15,31,32 14,33,34 1335 and
12 years old.36
The titles of some QoL instruments have been inaccurately
presented.37,38 Some authors did not provide references for the
QoL instruments that they have used.30,39
Most of the publications identified were clinical trials, epi-
demiologic studies and studies on creation and/or validation of
QoL instruments. However, there were also publications on edu-
cational work in acne patients,40–42 compliance and adherence
to treatment,36,43,44 correlation of QoL with acne severity mea-
sures,45,46 psychological problems,17,21,37,47–56 gender differ-
ences,57,58 racial differences,59 comparison of generic and
disease-specific QoL instruments,60,61 and comparison of QoL
impairment in patients with acne and other diseases.19,49,62–66
Clinical trials
The different interventions assessed, for which the greatest num-
ber of studies have been identified, were those concerning
isotretinoin31,48,50,67–76 and benzoyl peroxide.30,77–85
Epidemiological studies
A study from France showed that QUIMP in women with acne,
assessed by the DLQI, was significantly different from women
without acne.86 Another French study reported that patients’
daily lives were affected in nearly half of acne patients (48%).87
A study from Iraq found significant association between age and
QoL impairment in 510 acne patients.88 Acne influenced QoL
‘moderately’ to ‘very much’, in 51.8% of patients in a study from
Iran.89 On the other hand, 478 Serbian pupils with self-reported
acne reported low HRQoL impairment.90
Educational work in acne patients
Mean DLQI40,41 and CADI40 scores improved after 12 weeks of
text messages40 and multiple-choice questions.41 Internet-based
acne education using automated counselling was not superior to
standard website education in improving acne severity and QoL.42
Compliance and adherence to treatment
In patients with acne, being female, married, employed and not
paying for prescriptions were characteristics associated with
increased medication adherence and better HRQoL.36 Young
females with high Skindex-29 scale scores and males with low
Skindex scores are especially prone to non-adherence.43 Better
adherence was related to lower Skindex-29 scale scores at the
end of their study.43 Zaghoul et al. found significant negative
correlation between DLQI scores and medication adherence.36
Tan et al. reported that adherence increases with greater levels of
impact on acne-specific QoL assessed by the Acne-QoL ques-
tionnaire.44
Correlation of QoL with acne severity measures
In the majority of studies that addressed the issue, HRQoL cor-
related with acne severity.23,91,92 Hanisah et al. found that only
students with severe acne, assessed with the global acne grading
PubMed search for: “acne” and “quality of life”
Total: 527 papers
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for final analysis were included
Figure 1 Literature search procedure.
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Table 1 Details of HRQoL instruments that were used in articles reviewed
Titles of HRQoL
instruments







• One item from each of the WHOQOL-100 24
facets plus two benchmark items for overall QoL
and general health. The facets are subsumed into
four domains: Physical health, Psychological, Social
relations and Environment.
• Five-point Likert scale
• Scores from domains are transformed into a scale









• Six headings: Symptoms and feelings, Daily activi-
ties, Leisure, Work and School, Personal relation-
ships, Treatment
• Responses are on a four-point Likert scale
• Is calculated by summing the score of each ques-
tion resulting in a maximum of 30 and a minimum
of 0. The higher the score, the more QoL is
impaired
• Validated score band descriptors have been
described. For general inflammatory skin condi-
tions a change in DLQI score of at least four points











Skindex (61 items) • 61 items
• Eight scales (cognitive, social, physical discomfort,
physical limitation, depression, fear, embarrass-
ment and anger)
• Item responses are standardized from 0 (no effect)
to 100 (effect always experienced)
• A patient0s scale score was the average of his or her






Skindex-29 • 29 items
• Seven items address the Symptoms domain, ten
items the Emotional domain and twelve items the
Functioning domain
• Responses are on a five-point Likert scale
• All responses are transformed to a linear scale of
100, varying from 0 (no effect) to 100 (effect expe-
rienced all the time). Skindex scores are reported as
three scale scores, corresponding to the three
domains; a scale score is the average of a patient’s










Skindex-16 • 16 items
• Consists of the items that had the best performance
characteristics in the longer instrument, as well as
additional items that are not in Skindex-29. There
are three domains: symptoms (four items), emo-
tions (seven items) and functioning (five items)
• Responses are on a seven-point Likert
• All responses are transformed to a linear scale of
100, varying from 0 (no effect) to 100 (effect expe-
rienced all the time). Skindex scores are reported as
three scale scores, corresponding to the three
domains; a scale score is the average of a patient’s
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• Questions about feelings, relationships, social and
sporting activities
• Responses are on a linear analogue scale for each
item
• Score is calculated by summing the scores for each
item
• Test–retest reliability
• Correlation coefficient for overall
ADI score high
• Overall score correlated with over-
all UKSIP score
• Individual category score correla-







• Questions about feelings, social life and relation-
ships, skin exposure, overall severity
• Responses on a four point scale for each question
• Calculated by summing the score of each question
(0–3), resulting in a maximum score of 15 and a
minimum of 0
• Responsiveness to change
• Correlation with clinical severity
of acne and with UKSIP and
CDLQI
• Test–retest
• Correlation coefficient for overall
CADI score high
• Internal consistency
• Chinese, Serbian, Portuguese,
Ukrainian, Persian and French val-
idation: good reliability and inter-











• Four domains: self-perception, role-social, role-
emotional, acne symptoms
• Seven-point rating scale ranging from 0 = ‘ex-
tremely’ or ‘extensive’ to 6 = ‘not at all’ or ‘none’










index of the Acne-
QoL)
• Shortened form of the Acne-QoL
• Four items
• One item from each domain of Acne-QoL
• Seven-point rating scale ranging from 0 = ‘ex-
tremely’ or ‘extensive’ to 6 = ‘not at all’ or ‘none’
• Total index score: summing four items
• Construct validity 180–182
Acne Quality of Life
Scale (AQOL)
• nine items
• four-point rating scale: 0 = not at all, 1 = mildly,
2 = moderately, 3 = very markedly






Acne Quality of Life
Index (Acne-QOLI)
• 21 items
• Three dimensions: social functioning, psychological
functioning and emotional functioning
• Seven-point scale anchored with 1 = ‘Not at all’,
4 = ‘Some’ and 7 = ‘Extremely’










• Eight dimensions: Physical functioning, Social
functioning, Role limitations (physical problems),
Role limitations (emotional problems), Mental
health, Vitality, Pain and General health perception
• Three or six point scales
• Scores are then coded, summed and transformed to
a scale of 0 to 100 (worst and best health, respec-
tively)
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• Shorter form of the SF-36. Physical Functioning,
Role Physical, Role Emotional and Mental Health
are estimated with two items, while Bodily Pain,
General Health, Vitality and Social Functioning are









• Children (4–16 years)
• 10 items
• Questions are about symptoms, feelings, leisure
time, school and holidays, relationships, sleep and
treatment impact
• Responses are on a four-point Likert scale
• Is calculated by summing the score of each ques-
tion resulting in a maximum of 30 and a minimum
of 0. The higher the score, the more QoL is
impaired. Can also be expressed as a percentage of









Global QoL • eight items/domains: self-esteem, mood, relation-
ship with peers, relationships with family, work/
studies, lover relationships, money matters, health
• Responses are on a seven-point Likert scale






• Five items (two optional)
• Three domains: work/school
• social life
• family life
• 11 point visual analog scale
• The numerical ratings of 0–10 may be translated
into percentage











• Nine items scored on continuous linear visual ana-
logue scale (0–10)
• Six items scored by ticking boxes (each box was
allocated a score of 0, 3, 6 or 9)




• Child self-report (5–18 years)
• 23 items
• four domains: Physical functioning; Emotional
functioning, Social functioning and School func-
tioning
• Five-point Likert scale for children
• Items are reverse scored and linearly transformed










• Twelve domains: body care and movement, mobil-
ity, ambulation, emotional behaviour, social inter-
action, alertness behaviour, communication, sleep
and rest, home management, work, recreation and
pastime and eating. In addition to this, patients are
also asked to give an ‘overall health’ assessment,
from a range of ‘very good’ to ‘very poor’
• Scores can be easily expressed as a percentage,




• criterion validity (predictive/
concurrent)
• construct validity (convergent/dis-
criminant)
146
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system (GAGS), had high CADI scores.93 There was a positive
correlation between overall scores on the Echelle de Cotation des
Lesions d’Acne (ECLA) scale and CADI scales before and after
treatment in one study94 but no correlation in another study.58
Some studies found no correlation between the impairment of
QoL and the severity of acne.45,95,96 The report of a case–control
study in university students stated that even though the AQOL
and DLQI scores were significantly higher in acne patients com-
pared to controls, the level of impairment of QoL was not asso-
ciated with the severity of acne.45 In addition, there was no











• 29 items (17 psychosocial items and 12 activities
items)
• four psychosocial subscales (embarrassment, des-
pair, irritableness, distress) and four activities sub-
scales (everyday, summer, social, sexual)



















• Two parts: EQ-5D descriptive system and EQ visual
analogue scale (EQ-VAS). The descriptive system is
made up of five dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety/de-
pression
• Each dimension has three levels: no problems,
some problems and severe problems. Each response
is codified in a 1-digit number expressing the
selected level, resulting in a 5-digit number describ-
ing respondent’s health status. This codification
describes 243 different health states, ranging from
11 111 (full health) to 33 333 (worst health).
Numerals 1–3 have no arithmetic properties and
should be used as an ordinal score. The EQ-VAS
consists of a vertical, visual analogue scale where
the respondent can assess his or her own health sta-
tus. Its top point (100) is labelled ‘Best imaginable
health state’ and its bottom point (0) is labelled
‘Worst imaginable health state’
• convergent validity

























• symptoms (nine items)
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Psychological problems
A high impairment of dermatologic QoL seems to be associated
with an increased risk of having an anxiety disorder.51 Anger
was significantly related to both global QoL and skin-
related QoL in the study by Rapp et al.52 Bowe et al. showed
that Body Image Disturbance Questionnaire scores correlated
with Skindex-16 scores.97 Significant correlation was found
between Beck’s depression inventory and APSEA.76
Gender differences
In a population study of 1531 school pupils from Greece, the
HRQoLs of girls and boys were equally affected in those with
acne.91 Similarly, no difference was reported in other studies.95,98
In contrast, in several studies females were reported to experience
a greater impact on QoL than males.57,88,92,99,100 However in a
study carried out in Egypt, the mean DLQI scores of male pa-
tients with acne were higher than those of female patients.34
Racial and ethnic differences
Gorelick et al. explored the impact of racial background on the
perceived HRQoL impact of acne,101 categorising subjects into
‘White’, ‘Black’, ‘Hispanic’ and ‘Asian’. ‘White’ and ‘Black’ sub-
jects reported less negative impact of acne on QoL than ‘His-
panic’ and ‘Asian/other subjects’ measured by the Acne-
QoL. ’Black’ subjects reported significantly less negative impact
in the self-perception domain compared with ‘Asian/other sub-
jects’. By racial/ethnic group, social functioning was less nega-
tively impacted by acne in ‘White’ and ‘Black’ subjects than in
‘Asian/other subjects’. There were no statistically significant dif-
ferences in either the role-emotional or acne symptoms domains
among racial/ethnic groups.101 Callender et al. did not find sig-
nificant differences in HRQoL between white/Caucasian and
non-white/Caucasian women with acne.59
Comparison of generic and disease-specific QoL
instruments
Significant correlation in an acne population was reported
between all domains of the SF-36 and the DLQI scores.60 The
dermatology-specific instrument, the DLQI, was demonstrated
to be more responsive to change compared to the two generic
































































































































Figure 2 Number of studies in which each HRQoL instrument was used.
Task Forces recommendations for use of HRQoL measures in 
acne
Process of selection
Questionnaires should be selected that are appropriate for the ages 
of the subjects studied. Questionnaires should only be used within 
their validated age limits. 
When choosing questionnaires for use in research, investigators 
should ensure that they have been tested for scale structure, 
reliability, validity and responsiveness.208
Choice of measures
Use of validated acne-specific instruments in addition to generic and 
dermatology-specific questionnaires. 
The Task Forces recommend the DLQI, CDLQI and Skindex-29 as 
dermatology-specific, the CADI and Acne-QoL as acne-specific and 
SF-36 as generic instruments.
Publication
Authors should always clearly state the names of any QoL 
instruments used, along with the original reference to its publication. 
Editors should ensure that published QoL data at least meets these 
minimum requirements. 
Clinical use
The Task Forces encourage dermatologists to use HRQoL 
measurement in clinical practice, for many reasons15 and to educate 
trainees about the benefits of their use.
Figure 3 TFs recommendations for use of HRQoL measures in
acne.
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Comparison of QoL impairment in patients with acne and
other diseases
Patients with acne experienced functioning and emotional
effects from their skin disease comparable with those experi-
enced by patients with psoriasis, but had fewer symptoms.65
Patients with severe acne reported levels of social, psychological
and emotional problems that were as great as those reported by
patients with chronic disabling asthma, epilepsy, diabetes, back
pain or arthritis.63 In a study from Brazil, patients with acne had
the fourth highest QUIMP, surpassed only by psoriasis, vitiligo
and atopic dermatitis.102 In children psoriasis and atopic der-
matitis caused the greatest impairment of QoL, followed by urti-
caria and acne.19
Discussion
In all studies reviewed, the measures used detected impair-
ment of QoL caused by acne. Acne, especially when severe,
may have an impact on the life of patients comparable to that
caused by other dermatologic diseases, such as psoriasis, viti-
ligo, atopic dermatitis and urticaria19,65,102 and non-dermato-
logic diseases, such as asthma, epilepsy, diabetes, back pain
and arthritis.63 In a study by Sampogna et al.,103 the only skin
diseases that had a greater psychosocial impact than acne were
hyperhidrosis, hirsutism, ectoparasitic infections and bullous
diseases.
The DLQI, a dermatology-specific instrument, and the acne-
specific instruments CADI and Acne-QoL were used much more
frequently than the generic SF-36 questionnaire. The dermatol-
ogy-specific instruments CDLQI and Skindex-29 were also both
used more than 10 times. This may reflect a higher interest
amongst investigators in assessing dermatology- and acne-speci-
fic aspects of HRQoL impairment. Currently in routine clinical
practice HRQoL assessment is still infrequent despite there being
many potential benefits from such use.15
The dermatology-specific questionnaire the DLQI showed
greater response sensitivity following successful treatment than
the generic SF-36 and EQ-5D instruments.61 Appropriate
responses are especially important in clinical trials, the com-
monest reported context for QoL measurement in acne
patients. The instruments most used in clinical trials are the
DLQI and CADI.
The impairment of QoL in patients with acne has been
reported in epidemiologic studies in various countries.86–89,91,95
The impact on QoL correlates with acne severity in some but
not all studies, underlying the need for the effective and timely
management of acne even for patients with less severe
acne.86,87,91
The major impact of acne on HRQoL documented in the
reviewed studies emphasizes the need for educational pro-
grammes for acne patients about living with and treating
acne.40,41 An educational approach is currently much less devel-
oped than in atopic dermatitis or psoriasis. The creation and
critical evaluation of high-quality educational programmes




(brevity of the instrument is 
significant advantage)
Simultaneous use of 
generic, dermatology-
specific and acne-specific 
instruments is possible
Check if selected QoL instrument is appropriate for your 
patients age
Check availability of your national language version of 
selected QoL instrument and validation information
Yes No
Check conditions of its use
(e.g. fees may apply for 
clinical trials)
Contact authors to initiate 
translation and validation 
of your national language 




Figure 4 Flow chart to assist selection of appropriate HRQoL instrument.
© 2017 European Academy of Dermatology and VenereologyJEADV 2018, 32, 194–208
202 Chernyshov et al.
researchers and clinicians. QoL assessment may be used in this
context as an outcome measure and source of additional infor-
mation from patients. Prediction of compliance and adherence
to treatment in acne patients are another potential aspect of the
use of HRQoL instruments. However, current evidence suggests
that this is not an easy task.36,43,44 When starting a new treat-
ment, those patients with the most highly impaired HRQoL gen-
erally adhere better to the therapy. From a longer term
perspective, those patients whose acne improved the most
showed improvement in their HRQoL and had superior adher-
ence to therapy.
Impaired QoL is also often associated with significant psycho-
logical problems in acne patients.51,52,76,97 Gender differences
may also play a role. Although acne affects female and male ado-
lescents in about the same proportion, a higher impact on QoL
in females compared to males has been shown in several stud-
ies.57,88,92,99,100 No gender difference was found in other stud-
ies.91,95,98 There is only one report34 of male patients having a
greater impact of acne on their QoL, probably influenced by
regional peculiarities. It may be that racial and ethnic differences
in QoL assessment by acne patients101 are also based on differ-
ence in cultural attitudes.
As different studies examine different age ranges of subjects
and use different HRQoL questionnaires, there is little standard-
ization of results, emphasising the need for the development of
agreed core outcome measures for use across all studies.
During this review, many examples were identified of inap-
propriate use or reporting of QoL measurement in acne. These
included use of ‘study-specific’ unvalidated questionnaires that
included elements of QoL, inaccurate presentation of titles of
QoL instruments, absence of information on instruments and
use of QoL instruments out of their validated age limits. Simi-
lar problems were also reported concerning QoL measurement
in patients with atopic dermatitis.104 Such activity reduces the
scientific value of published results and may discredit HRQoL
assessment. There is a need for educated input when research-
ers plan studies that include HRQoL assessment and a need
for editors to set clear standards for the reporting of HRQoL
data.
On the basis of this literature review and expert opinion our
TFs recommend the DLQI, CDLQI and Skindex-29 as dermatol-
ogy-specific, CADI and Acne-QoL as acne-specific and SF-36 as
generic instruments for the assessment of HRQoL in acne. Expe-
rience of the use in acne of other instruments presented in this
study is too limited. The brevity of the DLQI, CDLQI and CADI
and Acne-QoL makes these instruments suitable for use in rou-
tine clinical practice. Acne-specific instruments may assess
HRQoL in both children and young adults.105 It is acknowl-
edged that some of the recommended measures may not have
ideal validation characteristics.
The recommendations of the TFs are given in Figs 3 and 4.
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